Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, May 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification fr ...

HOUSTON, May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the quarter ended March 31, 2024, on Friday, May 10, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, May 13, 20 ...

Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Company's AML clinical development program as well as data demonstrated to date Ongoing development progress of Annamycin toward pivotal AML study in 2024 with potential qualification for an accelerated approval pathway HOUSTON, May 2, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the ...

–     Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician memberHOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman. Dr. Tallman is an internationally renowned clini ...

–     Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects in a European clinical trial –     There are approximately 160,000 people with AML worldwide  –     Annamycin continues to show no signs of cardiotoxicity (N=82 across multiple studies); Lower toxicity profile than traditional intensive therapy –     Annamycin is advancing towards pivotal AML study in 2024 an ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Conference Call March 25, 2024 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman and CEO Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Vernon Bernardino - H.C. Wainwright Operator Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded. I'd now turn the conf ...

"Over the course of 2023 we established a significant growing body of positive clinical and encouraging safety data for Annamycin that continues to strengthen our confidence in the potential of our next generation, non-cardiotoxic chemotherapy in the treatment landscape for hard-to-treat cancers and viruses," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Building off of our momentum, we are laser focused on driving our priority pipeline programs toward key data milestones in th ...

Table of Contents (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from to Commission File Number: 001-37758 Moleculin Biotech, Inc. Securities registered pursuant to Section 12( ...

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO Paul Waymack - Senior CMO Jonathan Foster - EVP & CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Jason McCarthy - Maxim Group Jeff Jones - Oppenheimer Operator Greetings, and welcome to the Moleculin Biotech Third Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37758 5300 Memorial Drive, Suite 950 Houston, TX 77007 (Address of principal executive offices) (Zip Code) (IRS Empl ...